Due diligence in licensing pharmaceuticals

Watch this webinar by accessing the link at the bottom of this page. This is a recording of the live webinar held on 6 November 2012

Are you ready to find a partner or buyer for your company's pharmaceutical asset, but nervous about subjecting yourself to the dreaded process of due diligence? In this webinar, professionals with practical experience of handling technical and IP due diligence for 'Big Pharma' will provide an overview of the process, explain what information will be requested and why, and indicate how you can derive maximum benefit from your encounter with a potential suitor, regardless of the immediate outcome.


Oliver Kingsbury, Partner, Elkington Fife LLP

oliver kingsbury
Oliver Kingsbury is a partner with Elkington & Fife LLP. He read chemistry both as an undergraduate and as a postgraduate at St John's College, Oxford, obtaining his doctorate in organic chemistry in 1997.  He qualified as a UK and European Patent Attorney in 2002 and has spent most of his career working in the pharmaceutical industry, including a period on secondment to GlaxoSmithKline followed by full-time roles at Lilly and Pfizer.  Oliver has substantial experience in supporting business development activities through the provision of IP analysis and advice during due diligence projects for in-license/out-license opportunities and R&D collaborations. In 2011, Oliver left Pfizer to join Elkington and Fife LLP where he continues to practice patent law in the life sciences field. 


James Eshelby, Head of European R&D Business Development, Pfizer

James Eshelby
James joined Pfizer in 1997 and previously worked for Zeneca since 1989.  James has a PhD in Chemistry and is an inventor on nine patents. He is based at Pfizer's Neusentis research unit in Cambridge UK.   James is responsible for a team that evaluates and negotiates business deals for new partnerships and manages an extensive portfolio of licenses and alliances with Biotechs, Universities and other corporations.   James has a strong track record in leading business development activities on several major alliances and also for implementing open innovation and creative deals structures.


Bibiana Campos-Seijo, Editor, Chemistry World Magazine 

Bibiana Campos-Seijo
Bibiana is the editor of Chemistry World and magazines publisher for the RSC. After completing a PhD in chemistry, she ran her own e-learning business before moving into publishing first as a technical editor for the European Respiratory Society and then managing a portfolio of pharmaceutical titles at Advanstar Communications. In 2009, she moved to the RSC to lead the Magazines team. 

Also of interest

Industry and Technology

Supporting the scientific, technological and managerial application of chemical science across industry and commerce.

Webinar Partnership Programme

Join the Chemistry World webinar partnership programme; designed to connect you with your audience and to share topical information

Webinar archive

Watch here past Chemistry World webinars

Related Links

Link icon Watch webinar
Due diligence in licensing pharmaceuticals

External links will open in a new browser window